目的 調(diào)查分析南京地區(qū)2016—2018年47家醫(yī)院抗血小板與抗凝血藥物的臨床應(yīng)用情況與變化趨勢(shì)，為其臨床合理使用提供參考依據(jù)。方法 采用用藥頻度（DDDs）排序法與金額排序法，對(duì)南京地區(qū)47家醫(yī)院2016—2018年使用的抗血小板與抗凝血藥物的品種、銷售金額、構(gòu)成比、DDDs、限定日費(fèi)用（DDC）等進(jìn)行回顧性統(tǒng)計(jì)和分析。結(jié)果 2016—2018年，南京地區(qū)抗血小板與抗凝血藥物的年銷售金額逐年增長(zhǎng)率分別為9.02%與10.06%。氯吡格雷、低分子肝素、依諾肝素、利伐沙班、貝前列素鈉、阿加曲班、替格瑞洛7種藥物的銷售金額連續(xù)3年排在前列，且所占總銷售金額的比例3年均超過(guò)80%。氯吡格雷與華法林等藥物的DDDs值連續(xù)3年穩(wěn)居前列，且所占總DDDs的比例連續(xù)3年超過(guò)50%。氯吡格雷連續(xù)3年排序比（B/A）值為1.00，華法林的DDC值最低，比伐盧定的DDC值最高。結(jié)論 抗血小板與抗凝血藥物在南京地區(qū)醫(yī)院應(yīng)用廣泛，銷售金額與使用量整體上呈增長(zhǎng)后趨于平穩(wěn)的趨勢(shì)，大部分藥物的DDC呈降低趨勢(shì)。

Objective To evaluate the application and tendency of antiplatelet and anticoagulant drugs in 47 hospitals in Nanjing Area from 2016 to 2018. Methods The utilization of antiplatelet and anticoagulant drugs in 47 hospitals in Nanjing Area from 2016 to 2018 were analyzed statistically in respect of varieties, consumption sum, DDDs, etc. Results The annual in-creased rate of the consumption sum of antiplatelet and anticoagulant drugs was 9.02% and 10.06%, respectively. Top 7 drugs in the list were clopidogrel, low molecular weight heparin, enoxaparin, rivaroxaban, beraprost sodium, argatroban, ticagrelor. The total annual consumption sum exceeded 80%. Top 3 drugs in the list of total DDDs always were clopidogrel and warfarin. The total DDDs exceeded 50%. B/A values of clopidogrel is 1 in three years, warfarin has the lowest DDC and bivalirudin has the highest DDC. Conclusion Antiplatelet and anticoagulant drugs are widely used in hospitals in Nanjing Area. The sales and usage are increasing and tending to be stable, and the vast majority of daily drug cost is decreasing.

R973

南京大學(xué)醫(yī)院管理研究所管理項(xiàng)目（NDYG2019006）